Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

RECOMMENDED

Asthma

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Lancet Respir Med.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators

doi: 10.1016/S2213-2600

Asthma

Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials

Front Med.

Liu T, Wang F, Wang G, Mao H

doi: 10.1007/s11684-017-0565-0.

Asthma

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Lancet.

Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators

doi: 10.1016/

Asthma

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Lancet Respir Med.

FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M

doi: 10.1016/

RECOMMENDED

Asthma

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Eur Respir J.

Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG

doi: 10.1183/13993003.

Asthma

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Ann Allergy Asthma Immunol.

Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M

doi: 10.1016/j.anai.2018.01.030.

COMMENTED

Asthma

Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

J Asthma.

Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A

doi: 10.1080/02770903.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

N Engl J Med.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A

doi: 10.1056/NEJMoa1804092.

RECOMMENDED

Asthma

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Clin Pharmacol Ther.

Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L

doi: 10.1002/cpt.

Related content

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma